Tetratherix™

Q4 FY26 Quarterly Activities Report

Q4 FY26 Quarterly Activities Report

Tetratherix Limited (ASX: TTX) (**Tetratherix**) is pleased to release its Appendix 4C and quarterly activities report for the period ended 30 June 2026.

KEY HIGHLIGHTS FOR THE QUARTER (Q4 FY26)

01

The US FDA assigned a unique identifier number (UNII) for our Tetramatrix™ platform polymer (branded as STEPP) clearing a key regulatory requirement for US market entry

This formalises the substance registration with the FDA and enables the regulatory pathway for export to the US market for our Precision Medicine franchise. This is in addition to the recent successful issue of an official CAS registry number for the polymer which paves the path for our planned launch with Superpower Health Inc (**Superpower**) in Q1 FY27.

02

Tetratherix raised $15.6 million (before costs) via a secondary capital raise from new and existing institutional investors, strengthening Tetratherix's strong cash position to accelerate growth

Funds will be used to: expedite production capacity expansion; accelerate commercialisation of our Precision Medicine franchise; and strengthen the Tetratherix balance sheet.

03

Tetratherix received its first licence fee revenue of US$3 million (~A$4.2 million) in Q4 FY26

An acceleration of the previously communicated path to revenue on the Tetramatrix™ platform. This is an exciting launch of our exclusive research and development agreement with US consumer health group Superpower. The agreement focuses on the rapid collection of real-world evidence in the fast-evolving consumer health market through Superpower's intelligent health ecosystem.

04

Tutelix™ attained fast track ethics approval for the Tutelix™ international pivotal clinical trial (n=240) targeting FDA 510(k) clearance

Positive data from the TUTELA trial has identified the potential expansion of the Tutelix™ platform opportunity into gynaecological cancers representing an exciting entry into a grossly underserved market – a significant potential clinical impact in women's health.

"Q4 was a masterclass in relentless execution. Backed by an additional ~$15M in fresh capital and our first license revenue, the market has validated the Tetramatrix™ platform as a definitive paradigm shift in modern medicine.

We continue to accelerate the commercial scale across all TTX franchises. We achieved pivotal milestones for Tutelix™ while unlocking an expansive footprint in the grossly underserved segment of women's health. Tegenix and TegenEOS are marching aggressively toward FDA clearances and the export of STEPP is secured ahead of a US launch in coming months.

In addition, the new TTX campus location is nearing completion and our newly live enterprise infrastructure is fully operational on budget and on time.

This is the foundational blueprint of a highly scalable, revenue-generating engine that delivers compounding value for patients and shareholders alike as we rapidly propel towards commercial growth across the entire TTX ecosystem."

Will Knox
CEO of Tetratherix

Q4 FY26 Quarterly Activities Report

ADDITIONAL COMMENTARY FOR Q4 FY26

- Tegenix and TegenEOS (Bone Regeneration franchise) remain **on track for FDA 510(k) clearances** in CY26 following successful US performance studies and FDA dossier completion.
- **Independent studies validating the Tetramatrix™ platform potential for nasal drug delivery, protected by newly granted peptide–polymer patents.** Studies have confirmed that the Tetramatrix™ platform polymer forms a protective, adhesive carrier on the nasal lining. It shields fragile compounds from degradation and enables direct absorption into the bloodstream, without a needle. These publications add to a growing body of independent evidence validating Tetramatrix™ as a carrier platform for a broad range of therapeutic compounds, including proteins, peptides, hormones and growth factors. The publications coincide with new peptide–polymer patents granted to Tetratherix across multiple jurisdictions, strengthening the defensible intellectual property foundation for across the platform.
- **Expedited construction of the advanced manufacturing campus** in Alexandria, New South Wales, Australia. Incremental funding is being used to expedite additional manufacturing pods and headcount to support accelerating demand for the Tetramatrix™ platform, to automate quality and operations, driving efficiency. The campus will provide a substantial expansion of the Tetratherix manufacturing capability in production of the Tetramatrix™ polymer platform and finished goods inventory to meet anticipated global demand. The construction will meet regulatory and quality requirements and is expected to be certified and operational in CY26.
- **Medical Device Single Audit Program (MDSAP) Stage 1 audit completed by Bsi notified body.** Full stage 2 audit is expected in CY2027 for full accreditation of the Tetratherix campus. MDSAP allows a single regulatory audit to meet the requirements of multiple jurisdictions.
- **Strong cash position of $34.4 million as at 30 June 2026** including proceeds from May 2026 placement and Superpower licence revenue with zero debt financing.
- Tetratherix has completed the implementation of its Enterprise Resource Planning (**ERP**) system on time and on budget. The ERP will interface with the advanced manufacturing, quality systems and final export capabilities across the Tetratherix campus. Our ERP system integrates Tetratherix's manufacturing, inventory management, quality and financial processes.

Q4 FY26 Quarterly Activities Report

FINANCIAL COMMENTARY

Strong cash on hand position of $A 34.4 million as at 30 June 2026, with zero debt financing.

- **$19.3 million cash inflows in Q4; $21.9 million for full year FY26** driven by
  - $14.7m May 2026 placement (net of costs)*
  - $4.2m Inaugural Superpower licence fee*
  - $1.6m Industry Growth Program (IGP) grant*
  - $1.4m R&D tax incentive

  * 86% ($20.5 million) of inflows are incremental to prospectus assumptions.

- **($4.4) million cash outflows for Q4; ($17.1) million YTD FY26 in line with TTX's use of funds.**

Key drivers are continued investment in R&D, particularly Bone Regeneration (Tegenix and TegenEOS products), capital expenditure for TTX's new advanced manufacturing facility and ongoing listed costs and working capital expenditure.

TTX raised $15.6 million (before costs) through a secondary capital raise to expand production capacity and accelerate commercialisation of its Precision Medicine franchise, strengthening the balance sheet.

- The $15.0 million placement was conducted at $6.00 per share, a 2% discount to the 10-day VWAP, alongside a $0.6 million share purchase plan for existing eligible shareholders.
- These additional inflows will fund further growth beyond the commitments set out in the IPO strategic plan, accelerating Tetratherix's transition from an R&D to a commercially scalable organisation.
- These additional inflows will fund the next phase of expansion, primarily:
  - expedite production capacity and drive scale via strategic automation to meet added demand;
  - establish a customer success team to work with partners and regulatory bodies, supporting a sustainable and effective global presence;
  - build digital science organisational capability to improve operational efficiency and expand use cases across the platform; and
  - fund ongoing working capital and cover transaction costs.



In accordance with ASX Listing Rule 4.7C.3, Tetratherix advises that an amount of $340k was paid during the quarter to related parties and associates as disclosed in item 6.1 of the Appendix 4C. These payments comprised of: $290k for executive and non-executive directors' salaries, superannuation, and $50k in directors' salaries paid to entities associated with directors. For YTD FY26, payments to related parties and associates amounts to $1.8 million.

Q4 FY26 Quarterly Activities Report

Investor Hub

Tetratherix Investor Hub platform provides existing and prospective shareholders with real-time access to ASX announcements, reports and presentations. You can visit the Tetratherix Investor Hub at:

Authorised for release by the Board.

For further information contact:

Jacob Pfeffer
General Counsel | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com

FORWARD LOOKING STATEMENTS

This announcement may contain forward-looking statements which may be identified by words such as "believes", "considers", "could", "estimates", "expects", "intends", "may", and other similar words that involves risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Tetratherix or its Directors and management and could cause Tetratherix's actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurances that the results, performance, or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statement

APPENDIX 1

In accordance with ASX Listing Rule 4.7C Tetratherix provides the following use of funds (UOF) information:

USE OF FUNDS	Prospectus A$m	May-Jun 26 Actual Accumulated	as % prospectus	Ref
Research and Development Bone Regeneration	2.4	2.3	96%	1
Research and Development Tissue Healing	5.3	1.2	23%	2
Research and Development Tissue Spacing	2.3	0.9	40%	3
Research and Development Precision Medicine	1.3	1.1	83%	4
Manufacturing expansion	10.2	6.4	62%	5
Listed company costs and directors fees	2.5	1.7	68%	6
Costs of the offer ($0.4m expensed YTD Apr 25)	3.4	3.4	100%	7
Working capital	5.8	3.1	54%	8
Total Cash outflows	**33.2**	**20.2**	**61%**	9

REF	Comment
1 - 4	**R&D costs** include specific projects, directly attributable staff, research and laboratory costs, trademarks, patent filing, and upkeep. Specific breakdown by project as follows.
1	**Bone Regeneration:** activity focused on preparation for FDA clearance for Tegenix and TegenEOS, with spending front weighted in FY26.
2	**Tissue Healing**: ongoing clinical trial and pipeline development for TetraDerm.
3	**Tissue Spacing:** relates to Optelex clinical trials. Noting Tutelix™ is funded by the joint venture.
4	**Precision Medicine:** relates to nasal drug delivery R&D.
5	**Manufacturing expansion:** a new lease was signed in August 2025. Capital expenditure investment has commenced to commission our advanced manufacturing facility.
6	**Listed company costs**: Reflects board remuneration, audit fees, share registry, directors' and officers' insurance and company secretary services.
7	**IPO costs:** All invoices have now been paid; in line with prospectus assumptions.
8	**Working capital**: Includes staff (ex R&D), interest, and general operating expenses.
9	**Proceeds from the IPO of $33.2m** included $8.2m existing cash on hand as at 30/4/25 as per prospectus plus $25 million capital raise funding 30/6/2025. **$34.4m Closing cash balance** as at 30 June 2026. **Cash outflows**: May 2025- June 2026 cumulative total ($20.2)m including ($4.4)m in Q4 FY26 per UOF table above. Funds raised at the IPO continue to deployed as disclosed in the prospectus. **Cash inflows** May 2025- June 2026 cumulative total $21.9m including $19.3m in Q4 FY26 • $14.7m cash injection from May 2026 placement* • $4.2m Superpower licence fee receipt * • $1.6 m from Industry growth program grant * • $1.4 m from R&D tax incentive * **Incremental funding versus prospectus** at **86% of inflows ($20.5 million)** These additional inflows will fund further growth beyond the commitments set out in the IPO strategic plan, accelerating Tetratherix's transition from an R&D to a commercially scalable organisation.

APPENDIX 4C QUARTERLY CASH FLOW REPORT FOR ENTITIES SUBJECT TO LISTING RULE 4.7B

Name of entity	
Tetratherix™	
ABN	**Date**
72 607 771 077	Jun 30, 2026

	Consolidated statement of cash flows	Current quarter $A'000	Year to date (12 months) $A'000
1	**Cash flows from operating activities**		
1.1	Receipts from customers	4,198	4,201
1.2	Payments for	-	-
1.2 (a)	- research and development	(1,312)	(3,162)
1.2 (b)	- product manufacturing and operating costs	-	-
1.2 (c)	- advertising and marketing	(135)	(435)
1.2 (d)	- leased assets	(305)	(754)
1.2 (e)	- staff costs	(1,252)	(4,799)
1.2 (f)	- administration and corporate costs	(681)	(2,154)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	214	795
1.5	Interest and other costs of finance paid	-	(15)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	443	3,229
1.8	Other (provide details if material)	2	(29)
1.9	**Net cash from / (used in) operating activities**	**1,172**	**(3,123)**

2	**Cash flows from investing activities**	**Current quarter**	**Year to date (12 months)**
2.1	Payments to acquire or for:		
2.1 (a)	- entities	-	-
2.1 (b)	- businesses	-	-
2.1 (c)	- property, plant and equipment	(818)	(4,428)
2.1 (d)	- investments	-	(820)
2.1 (e)	- intellectual property	(76)	(1,126)
2.1 (f)	- other non-current assets	-	-

APPENDIX 4C QUARTERLY CASH FLOW REPORT FOR ENTITIES SUBJECT TO LISTING RULE 4.7B

	Cash flows from investing activities (Cont.)	Current quarter	Year to date (12 months)
		$A'000	$A'000
2.2	Proceeds from disposal of:	-	-
2.2 (a)	- entities	-	-
2.2 (b)	- businesses	-	-
2.2 (c)	- property, plant and equipment	-	-
2.2 (d)	- investments	-	-
2.2 (e)	- intellectual property	-	-
2.2 (f)	- other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (Contingent consideration payments)	-	-
2.6	**Net cash from / (used in) investing activities**	**(894)**	**(6,374)**

3	Cash flows from financing activities	Current quarter	Year to date (12 months)
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	15,640	15,640
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(916)	(1,272)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (leased assets)	-	-
3.1	**Net cash from / (used in) financing activities**	**14,724**	**14,368**

4	Net increase / (decrease) in cash and cash equivalents for the period	Current quarter	Year to date (12 months)
4.1	Cash and cash equivalents at beginning of period	19,206	29,337
4.2	Net cash from operating activities (item 1.9 above)	1,172	(3,123)
4.3	Net cash used in investing activities (item 2.6 above)	(894)	(6,374)
4.4	Net cash from financing activities (item 3.1 above)	14,724	14,368
4.5	Effect of movement in exchange rates on cash held	156	156
4.6	**Cash and cash equivalents at end of period**	**34,364**	**34,364**

APPENDIX 4C QUARTERLY CASH FLOW REPORT FOR ENTITIES SUBJECT TO LISTING RULE 4.7B

5	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter	Previous quarter
		$A'000	$A'000
5.1	- Bank balances	34,314	19,156
5.2	- Call deposits	50	50
5.3	- Bank overdrafts	-	-
5.4	- Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	34,364	19,206

6	Payments to related parties of the entity and their associates	Current quarter
		$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	340
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
6.1 Note	These payments comprised of: $290k for executive and non-executive directors' salaries, superannuation, and $50k in directors' fees paid to entities associated with directors.	

7	Financing facilities Note: the term "facility" includes all forms of financing arrangements available to the entity.	Total facility amount at quarter end	Amount drawn at quarter end
	Add notes as necessary for an understanding of the sources of finance available to the entity.	$A'000	$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end	-	-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	N/A	

APPENDIX 4C QUARTERLY CASH FLOW REPORT FOR ENTITIES SUBJECT TO LISTING RULE 4.7B

8	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	1,172
8.2	Cash and cash equivalents at quarter end (item 4.6)	34,364
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	34,364
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	N/A
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	N/A	
	Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.	

Q4 FY26 Quarterly Activities Report

COMPLIANCE STATEMENT

1. This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
2. This statement gives a true and fair view of the matters disclosed.

Date: 22 July 2026

Authorised by: Board

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.